California food technology company Perfect Day recently announced it had subleased from Aduro Biotech 112,000 square feet of office and laboratory space at 740 Heinz Ave. in Berkeley, Calif. The sublease represents all of the space leased by Aduro in the Aquatic Park Center campus which totals 800,000 square feet of office space in 16 buildings.
Perfect Day will vacate its current 23,000-square-foot operation in Emeryville, Calif. Its new space in Berkeley is to be made available to the company in three phases: approximately 60,000 square feet will be delivered this year, another 37,000 square feet will be ready in 2021 and the remainder will be vacated in 2022. The sublease runs through 2029.
Lisa Vogel, director of Wareham Development, which owns Aquatic Park Center, said, “We’re delighted to welcome another innovative East Shore company, one doing important work in advancing the boundaries of sustainable food production technology.”
The new tenant also said in a statement, “This expanded footprint will continue to help accelerate Perfect Day’s business growth — including continuing to expand production capacity, solidifying new partners, and extending its product portfolio.”
Situated in southwestern Berkeley, the Aquatic Park Center offers laboratory and office space for lease in San Francisco to a multitude of companies operating on the West Coast. Specifically, the property at 740 Heinz Ave. was designed as a state-of-the-art R&D facility for life science companies and features amenities such as outdoor terraces, a plaza, an on-site child care facility and easy access to the inner courtyard of the Aquatic Park Center campus. The restaurants and cafes at 800-830 Heinz Ave. are also within easy reach.
Perfect Day is a California food technology startup specializing in animal-free dairy products, operating in a business-to-business model. The Berkeley sublease is part of the firm’s expansion plans.
Aduro Biotech operates in immunotherapy-based cancer treatments. The company is reportedly subleasing its Berkeley offices that it has occupied since 2015 in preparation for a merger with Canadian biotech company Chinook Therapeutics.